Edgar Filing: TECOGEN INC. - Form 8-K

TECOGEN INC.
Form 8-K
November 13, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 8, 2013

TECOGEN INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

333-178697 04-3536131

(Commission File Number) (IRS Employer Identification No.)

45 First Avenue

Waltham, Massachusetts 02451 (Address of Principal Executive Offices) (Zip Code)

(781) 622-1120

(Registrant's telephone number, including area code)

\_\_\_\_\_

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

## Edgar Filing: TECOGEN INC. - Form 8-K

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: TECOGEN INC. - Form 8-K

Item 1.01. Entry into a Material Definitive Agreement.

On November 8, 2013, Tecogen Inc., or the Company, entered into common stock purchase agreements, or the Common Stock Purchase Agreements, with certain accredited investors, collectively, the Investors. Pursuant to the Common Stock Purchase Agreements, the Company sold, and the Investors purchased, an aggregate of 441,600 shares of the Company's common stock, \$.001 par value, or the Shares, at a price of \$4.50 per share for an aggregate purchase price of \$1,987,200, or the Private Placement. The proceeds of the Private Placement will be used for general corporate and working capital purposes.

The Common Stock Purchase Agreements require the Company to file a registration statement with the Securities and Exchange Commission covering the resale of the Shares by the Investors.

Pursuant to an arrangement with the Company, the Company is required to pay a fee equal to 6.75% of the gross proceeds from the Private Placement, or an aggregate of \$134,136, to certain investment banks engaged by the Company in connection with a previous offering.

The summary of the Common Stock Purchase Agreements set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Common Stock Purchase Agreement attached as Exhibit 10.1.

Item 3.02 Unregistered Sales of Equity Securities.

The offer and sale of the Shares described in Item 1.01 of this Current Report on Form 8-K was made in a private placement without registration under the Securities Act of 1933, as amended, or the Securities Act, or state securities laws, in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The Shares may not be re-offered or sold in the United States absent an effective registration statement or an exemption from the registration requirements under applicable federal and state securities laws.

The information in Item 1.01 of this Current Report on Form 8-K is incorporated herein by this reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description of Exhibit

10.1 Form of Common Stock Purchase Agreement

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

TECOGEN INC.

By: /s/ Bonnie J. Brown

Date: November 13, 2013 Bonnie J. Brown, Chief Financial Officer